Smartlens’ flagship product, miLens, is the world’s first electronics-free soft contact lens capable of continuous intraocular pressure (IOP) measurement. The microfluidic lens pairs with the firm’s AI-powered smartphone imaging platform to capture real-time pressure data and deliver predictive analytics for glaucoma and ocular-hypertension patients. The company is running a multi-site U.S. pivotal trial and has advanced regulatory preparation, manufacturing scale-up, and clinical validation. Market demand appears strong: a Market Scope survey of 166 ophthalmic practitioners showed 96.2 % intend to adopt miLens once available. After securing FDA clearance, Smartlens plans an expedited commercial launch and expects its platform to enable earlier, data-driven interventions that could slow disease progression for the 180 million people affected by glaucoma and ocular hypertension worldwide. The recent $5.2 million bridge financing provides the capital needed to complete the clearance process and prepare for market entry.

Total raised

$11M

Funding rounds

2

Latest round

Equity

Latest activity

Oct 2025